AAVantgarde Founder and Chief Scientific Officer, Professor Alberto Auricchio, is elected as President of the European Society of Gene and Cell Therapy
28. Oktober 2024 03:00 ET
|
AAVantgarde Bio
AAVantgarde Founder and Chief Scientific Officer, Professor Alberto Auricchio, is elected as President of the European Society of Gene and Cell Therapy
AAVantgarde appoints Ms. Lauren Kaskiel as Chief Business Officer
21. Oktober 2024 02:00 ET
|
AAVantgarde Bio
AAVantgarde appoints Ms. Lauren Kaskiel as Chief Business Officer
AAVantgarde announces 3 oral presentations at ESGCT 2024 annual meeting
08. Oktober 2024 02:00 ET
|
AAVantgarde Bio
MILAN, Oct. 08, 2024 (GLOBE NEWSWIRE) -- AAVantgarde Bio (AAVantgarde), a clinical-stage, Italian-based international biotechnology company with two proprietary Adeno-Associated Viral (AAV) vector...
AAVantgarde announces first patient dosed in First-In-Human Phase 1/2 LUCE-1 study, evaluating AAVB-081 (Dual-AAV) in retinitis pigmentosa related to Usher Syndrome type 1B
16. September 2024 02:00 ET
|
AAVantgarde Bio
AAVantgarde announces first patient dosed in First-In-Human Phase 1/2 LUCE-1 study
AAVantgarde appoints Dr. Jayashree Sahni as Chief Medical Officer
09. September 2024 02:00 ET
|
AAVantgarde Bio
AAVantgarde appoints Dr. Jayashree Sahni as Chief Medical Officer
AAVantgarde announces its innovative clinical study design for its lead program in Usher 1B
03. Mai 2024 03:00 ET
|
AAVantgarde Bio
AAVantgarde announces its innovative clinical study design for its lead program in Usher 1B
AAVantgarde announces updated NHP data from its Stargardt disease program in a poster presentation at the ARVO 2024 annual meeting
24. April 2024 02:00 ET
|
AAVantgarde Bio
AAVantgarde announces updated NHP data from its Stargardt disease program in a poster presentation at the ARVO 2024 annual meeting
AAVantgarde presents positive preclinical data in large animal models from its Stargardt disease program in an oral presentation at the ASGCT 2024 annual meeting
23. April 2024 02:00 ET
|
AAVantgarde Bio
AAVantgarde presents positive preclinical data in large animal models from its Stargardt disease program in an oral presentation at ASGCT 2024
AAVantgarde Closes €61 Million Series A Financing to Advance Two Therapeutic Programs into the Clinic
06. Juni 2023 08:00 ET
|
AAVantgarde Bio
- Financing led by Atlas Venture and Forbion - Company created, incubated and seed financed by Sofinnova Partners MILAN, Italy, June 06, 2023 (GLOBE NEWSWIRE) -- AAVantgarde Bio (AAVantgarde), a...